Feline
Update (June 16, 2026): An Oral Telmisartan Suppression Test Shows Promise for Diagnosing Primary Hyperaldosteronism in Cats
TL;DR. A proof-of-concept feline study suggests an oral telmisartan suppression test could help diagnose primary hyperaldosteronism, while a separate glaucoma study reaffirms telmisartan's blood-pressure tolerability in cats.
What just dropped
- Prospective placebo-controlled crossover study (https://europepmc.org/articles/PMC10365039): in healthy cats, an oral telmisartan dose significantly lowered plasma aldosterone, whereas in cats with primary hyperaldosteronism it produced no significant change, supporting a telmisartan suppression test for diagnosis.
- No adverse effects such as hyperkalemia or systemic hypotension were observed in any cat in that study.
- A six-month feline glaucoma study (https://europepmc.org/articles/PMC11407481) found daily oral telmisartan was well tolerated and did not have a detrimental effect on blood pressure or ocular perfusion pressure, though it did not lower intraocular pressure.
Context
Telmisartan (Semintra) is an angiotensin II type 1 receptor blocker licensed in cats for systemic hypertension and for proteinuria associated with chronic kidney disease. Two recent studies probe its angiotensin-axis pharmacology in cats from new angles.
In the Fabres 2023 study, 10 healthy cats and 6 cats with primary hyperaldosteronism (PHA) underwent a telmisartan suppression test. A telmisartan dose suppressed aldosterone in healthy cats but not in PHA cats, mirroring how human aldosterone-suppression testing works and offering a possible tool for a condition that remains difficult to diagnose. The Oikawa 2024 study, while focused on glaucoma rather than diagnosis, independently confirms that telmisartan was well tolerated and did not adversely affect blood pressure or ocular perfusion pressure over six months in cats, including a cohort with spontaneous glaucoma.
What this changes in telmisartan (Semintra) for proteinuria and hypertension in cats with CKD (https://www.thevoyage.ai/forvets/knowledge/telmisartan-feline-ckd-proteinuria)
These data extend the picture of telmisartan in cats beyond its labeled blood-pressure and proteinuria roles: a potential diagnostic application in suspected hyperaldosteronism, plus reassurance on blood-pressure tolerability from an independent six-month cohort. The suppression test is proof-of-concept and not a validated clinical protocol, and none of this changes approved dosing, which remains a label and formulary decision.
Voyage Clinical Desk
From clinical question to SOAP draft -- cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.
Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-16-telmisartan-aldosterone-suppression-cats
References
- Fabres V, Dumont R, Garcia M, et al. Evaluation of oral telmisartan administration as a suppression test for diagnosis of primary hyperaldosteronism in cats. J Vet Intern Med. 2023;37(4):1341-1347. https://europepmc.org/articles/PMC10365039
- Oikawa K, Kiland JA, Mathu V, et al. Effects of Telmisartan on Intraocular Pressure, Blood Pressure, and Ocular Perfusion Pressure in Normal and Glaucomatous Cats. Transl Vis Sci Technol. 2024;13(9):15. https://europepmc.org/articles/PMC11407481
Related reads
References
- Fabres V, Dumont R, Garcia M, et al. Evaluation of oral telmisartan administration as a suppression test for diagnosis of primary hyperaldosteronism in cats. J Vet Intern Med. 2023. (2023)
- Oikawa K, Kiland JA, Mathu V, et al. Effects of Telmisartan on Intraocular Pressure, Blood Pressure, and Ocular Perfusion Pressure in Normal and Glaucomatous Cats. Transl Vis Sci Technol. 2024. (2024)
More clinical updates
Update (June 17, 2026): Adjunctive FMT Reduces Lesion Severity and Medication Use in Canine Atopic Dermatitis — First RCT
A June 2026 double-blinded RCT (40 dogs) found adjunctive faecal microbiota transplantation reduced CADESI-04 scores and medication requirements in cAD versus placebo.
Read →Update (June 17, 2026): Lymph Food RCT Improves Lesion Scores and Reduces Medication Use in Dogs with Atopic Dermatitis
Frizzo-Ramos 2025 (112-day RCT, 38 dogs): lymph food supplement added to standard cAD care reduced CADESI-4 by 55% vs +26% placebo (p<0.0003) and cut medication use.
Read →Update (June 17, 2026): Bedinvetmab Plus Physiotherapy Outperforms Bedinvetmab Alone on Pain Threshold in Dogs With Hip OA
Cidral 2026 RCT (30 dogs): bedinvetmab + photobiomodulation/PEMF superior to bedinvetmab alone on algometry from Day 30 (p=0.027), more pronounced at D60-90 (p<0.001).
Read →Update (June 17, 2026): Survey of 373 Vets Finds Wide Canine OA Practice Variation — Bedinvetmab Paresis/Ataxia Signal at 31%
Bird 2026 survey (373 vets): NSAIDs dominate canine OA Rx; bedinvetmab perceived neurological AEs at 31%; grapiprant GI AEs (diarrhea 33%, vomiting 31%) most reported.
Read →